601607.SH上海证券交易所 · 主板 Main
Shanghai Pharma 上海医药
Pharmaceutical Distribution 医药商业
¥16.02−¥0.04 · −0.25%
Open 开盘
¥16.06
High 最高
¥16.14
Low 最低
¥15.98
Prev Close 昨收
¥16.06
Volume 成交量
672.2万股
Turnover 成交额
¥1.08亿
Mkt Cap 总市值
¥594亿
P/E 市盈率
12.4×
Recent Activity 近期动态All Filings 全部公告 →
8 significant filings since 29 May 2026: 2 on regulatory inquiry, 3 on dividend and 2 on major holder buying, and 1 other kind. The latest, on 11 Sep 2026: 上海医药集团股份有限公司2026年半年度权益分派实施公告. 1 unverified report logged, the latest on 20 Aug 2026.
自 29 May 2026 起有 8 份重大公告：regulatory inquiry 2 份、dividend 3 份、major holder buying 2 份，另有 1 类。最新一份（11 Sep 2026）：上海医药集团股份有限公司2026年半年度权益分派实施公告。记录了 1 条未经核实的报道，最新一条见于 20 Aug 2026。
15.0015.5016.0016.5017.0017.50
Volume 成交量
5,175.9万
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Pharmaceutical Distribution 医药商业 · 30 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥594亿 | ¥59亿 | Highest of 30 · 30 家中第 1 高 | |
| Trailing P/E 市盈率 | 12.4x | 22.9x | 6th lowest of 25 · 25 家中第 6 低 | |
| P/B 市净率 | 0.8x | 1.2x | 2nd lowest of 30 · 30 家中第 2 低 | |
| Revenue Growth 营收增速 | 4.2% | 0.3% | 7th highest of 30 · 30 家中第 7 高 | |
| Profit Growth 净利增速 | -21.4% | -7.2% | 7th lowest of 30 · 30 家中第 7 低 | |
| Gross Margin 毛利率 | 11.0% | 11.2% | 15th lowest of 30 · 30 家中第 15 低 | |
| Net Margin 净利率 | 2.9% | 1.6% | 11th highest of 30 · 30 家中第 11 高 | |
| Return on Equity 净资产收益率 | 4.5% | 3.0% | 9th highest of 30 · 30 家中第 9 高 | |
| Debt to Assets 资产负债率 | 61.5% | 61.0% | 15th highest of 30 · 30 家中第 15 高 | |
| Grade Score 评级得分 | 56 | 47 | 11th highest of 30 · 30 家中第 11 高 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥594亿 | 12.4x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥268亿 | 15.2x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥244亿 | 12.1x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥200亿 | 14.7x | 2.6x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥194亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| Qingdao Baheal Medical 百洋医药 | ¥133亿 | 24.7x | 5.8x | -5.1% | 7.9% | 9.3% | C |
| China Meheco 中国医药 | ¥133亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥98亿 | 22.8x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.8x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥83亿 | 29.7x | 3.8x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.2x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥62亿 | 22.9x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.3x | 0.8x | 2.2% | 3.5% | 4.6% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。